Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Türeci Ö[au]:

Search results

Items: 1 to 50 of 123

1.

A Trans-amplifying RNA Vaccine Strategy for Induction of Potent Protective Immunity.

Beissert T, Perkovic M, Vogel A, Erbar S, Walzer KC, Hempel T, Brill S, Haefner E, Becker R, Türeci Ö, Sahin U.

Mol Ther. 2019 Sep 12. pii: S1525-0016(19)30412-5. doi: 10.1016/j.ymthe.2019.09.009. [Epub ahead of print]

PMID:
31624015
2.

Personalized Neo-Epitope Vaccines for Cancer Treatment.

Vormehr M, Diken M, Türeci Ö, Sahin U, Kreiter S.

Recent Results Cancer Res. 2020;214:153-167. doi: 10.1007/978-3-030-23765-3_5.

PMID:
31473852
3.

HPV16 RNA-LPX vaccine mediates complete regression of aggressively growing HPV-positive mouse tumors and establishes protective T cell memory.

Grunwitz C, Salomon N, Vascotto F, Selmi A, Bukur T, Diken M, Kreiter S, Türeci Ö, Sahin U.

Oncoimmunology. 2019 Jul 11;8(9):e1629259. doi: 10.1080/2162402X.2019.1629259. eCollection 2019.

4.

A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study.

Türeci O, Sahin U, Schulze-Bergkamen H, Zvirbule Z, Lordick F, Koeberle D, Thuss-Patience P, Ettrich T, Arnold D, Bassermann F, Al-Batran SE, Wiechen K, Dhaene K, Maurus D, Gold M, Huber C, Krivoshik A, Arozullah A, Park JW, Schuler M.

Ann Oncol. 2019 Sep 1;30(9):1487-1495. doi: 10.1093/annonc/mdz199.

5.

Intravenous delivery of the toll-like receptor 7 agonist SC1 confers tumor control by inducing a CD8+ T cell response.

Vascotto F, Petschenka J, Walzer KC, Vormehr M, Brkic M, Strobl S, Rösemann R, Diken M, Kreiter S, Türeci Ö, Sahin U.

Oncoimmunology. 2019 Apr 19;8(7):1601480. doi: 10.1080/2162402X.2019.1601480. eCollection 2019.

PMID:
31143525
6.

Comparison of Claudin 18.2 expression in primary tumors and lymph node metastases in Japanese patients with gastric adenocarcinoma.

Rohde C, Yamaguchi R, Mukhina S, Sahin U, Itoh K, Türeci Ö.

Jpn J Clin Oncol. 2019 Sep 1;49(9):870-876. doi: 10.1093/jjco/hyz068.

7.

Challenges towards the realization of individualized cancer vaccines.

Türeci Ö, Löwer M, Schrörs B, Lang M, Tadmor A, Sahin U.

Nat Biomed Eng. 2018 Aug;2(8):566-569. doi: 10.1038/s41551-018-0266-2. No abstract available.

PMID:
31015635
8.

A non-functional neoepitope specific CD8+ T-cell response induced by tumor derived antigen exposure in vivo.

Vormehr M, Reinhard K, Blatnik R, Josef K, Beck JD, Salomon N, Suchan M, Selmi A, Vascotto F, Zerweck J, Wenschuh H, Diken M, Kreiter S, Türeci Ö, Riemer AB, Sahin U.

Oncoimmunology. 2018 Dec 24;8(3):1553478. doi: 10.1080/2162402X.2018.1553478. eCollection 2019.

PMID:
30723585
9.

Harnessing Tumor Mutations for Truly Individualized Cancer Vaccines.

Vormehr M, Türeci Ö, Sahin U.

Annu Rev Med. 2019 Jan 27;70:395-407. doi: 10.1146/annurev-med-042617-101816.

PMID:
30691374
10.

Improving mRNA-Based Therapeutic Gene Delivery by Expression-Augmenting 3' UTRs Identified by Cellular Library Screening.

Orlandini von Niessen AG, Poleganov MA, Rechner C, Plaschke A, Kranz LM, Fesser S, Diken M, Löwer M, Vallazza B, Beissert T, Bukur V, Kuhn AN, Türeci Ö, Sahin U.

Mol Ther. 2019 Apr 10;27(4):824-836. doi: 10.1016/j.ymthe.2018.12.011. Epub 2018 Dec 18.

11.

A phase I dose-escalation study of IMAB362 (Zolbetuximab) in patients with advanced gastric and gastro-oesophageal junction cancer.

Sahin U, Schuler M, Richly H, Bauer S, Krilova A, Dechow T, Jerling M, Utsch M, Rohde C, Dhaene K, Huber C, Türeci Ö.

Eur J Cancer. 2018 Sep;100:17-26. doi: 10.1016/j.ejca.2018.05.007. Epub 2018 Jun 21.

12.

Enhanced stability of a chimeric hepatitis B core antigen virus-like-particle (HBcAg-VLP) by a C-terminal linker-hexahistidine-peptide.

Schumacher J, Bacic T, Staritzbichler R, Daneschdar M, Klamp T, Arnold P, Jägle S, Türeci Ö, Markl J, Sahin U.

J Nanobiotechnology. 2018 Apr 13;16(1):39. doi: 10.1186/s12951-018-0363-0.

13.

Personalized vaccines for cancer immunotherapy.

Sahin U, Türeci Ö.

Science. 2018 Mar 23;359(6382):1355-1360. doi: 10.1126/science.aar7112. Review.

PMID:
29567706
14.

Erratum: Elimination of large tumors in mice by mRNA-encoded bispecific antibodies.

Stadler CR, Bähr-Mahmud H, Celik L, Hebich B, Roth AS, Roth RP, Karikó K, Türeci Ö, Sahin U.

Nat Med. 2017 Oct 6;23(10):1241. doi: 10.1038/nm1017-1241d.

PMID:
28985209
15.

Improvement of In Vivo Expression of Genes Delivered by Self-Amplifying RNA Using Vaccinia Virus Immune Evasion Proteins.

Beissert T, Koste L, Perkovic M, Walzer KC, Erbar S, Selmi A, Diken M, Kreiter S, Türeci Ö, Sahin U.

Hum Gene Ther. 2017 Dec;28(12):1138-1146. doi: 10.1089/hum.2017.121. Epub 2017 Sep 6.

16.

Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer.

Sahin U, Derhovanessian E, Miller M, Kloke BP, Simon P, Löwer M, Bukur V, Tadmor AD, Luxemburger U, Schrörs B, Omokoko T, Vormehr M, Albrecht C, Paruzynski A, Kuhn AN, Buck J, Heesch S, Schreeb KH, Müller F, Ortseifer I, Vogler I, Godehardt E, Attig S, Rae R, Breitkreuz A, Tolliver C, Suchan M, Martic G, Hohberger A, Sorn P, Diekmann J, Ciesla J, Waksmann O, Brück AK, Witt M, Zillgen M, Rothermel A, Kasemann B, Langer D, Bolte S, Diken M, Kreiter S, Nemecek R, Gebhardt C, Grabbe S, Höller C, Utikal J, Huber C, Loquai C, Türeci Ö.

Nature. 2017 Jul 13;547(7662):222-226. doi: 10.1038/nature23003. Epub 2017 Jul 5.

PMID:
28678784
17.

Elimination of large tumors in mice by mRNA-encoded bispecific antibodies.

Stadler CR, Bähr-Mahmud H, Celik L, Hebich B, Roth AS, Roth RP, Karikó K, Türeci Ö, Sahin U.

Nat Med. 2017 Jul;23(7):815-817. doi: 10.1038/nm.4356. Epub 2017 Jun 12. Erratum in: Nat Med. 2017 Oct 6;23 (10 ):1241.

PMID:
28604701
18.

Discovery and Subtyping of Neo-Epitope Specific T-Cell Responses for Cancer Immunotherapy: Addressing the Mutanome.

Diken M, Vormehr M, Grunwitz C, Kreiter S, Türeci Ö, Sahin U.

Methods Mol Biol. 2017;1499:223-236.

PMID:
27987153
19.

The European Regulatory Environment of RNA-Based Vaccines.

Hinz T, Kallen K, Britten CM, Flamion B, Granzer U, Hoos A, Huber C, Khleif S, Kreiter S, Rammensee HG, Sahin U, Singh-Jasuja H, Türeci Ö, Kalinke U.

Methods Mol Biol. 2017;1499:203-222. Review.

PMID:
27987152
20.

Past, present and future of immunology in Mainz.

Waisman A, Hövelmeyer N, Diefenbach A, Schuppan D, Reddehase MJ, Kleinert H, Kaina B, Grabbe S, Galle PR, Theobald M, Zipp F, Sahin U, Türeci Ö, Kreiter S, Langguth P, Decker H, van Zandbergen G, Schild H.

Cell Immunol. 2016 Oct;308:1-6. doi: 10.1016/j.cellimm.2016.09.001. No abstract available.

PMID:
27719802
21.

Uptake of synthetic naked RNA by skin-resident dendritic cells via macropinocytosis allows antigen expression and induction of T-cell responses in mice.

Selmi A, Vascotto F, Kautz-Neu K, Türeci Ö, Sahin U, von Stebut E, Diken M, Kreiter S.

Cancer Immunol Immunother. 2016 Sep;65(9):1075-83. doi: 10.1007/s00262-016-1869-7. Epub 2016 Jul 15.

PMID:
27422115
22.

Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy.

Kranz LM, Diken M, Haas H, Kreiter S, Loquai C, Reuter KC, Meng M, Fritz D, Vascotto F, Hefesha H, Grunwitz C, Vormehr M, Hüsemann Y, Selmi A, Kuhn AN, Buck J, Derhovanessian E, Rae R, Attig S, Diekmann J, Jabulowsky RA, Heesch S, Hassel J, Langguth P, Grabbe S, Huber C, Türeci Ö, Sahin U.

Nature. 2016 Jun 16;534(7607):396-401. doi: 10.1038/nature18300. Epub 2016 Jun 1.

PMID:
27281205
23.

FLT3 Ligand as a Molecular Adjuvant for Naked RNA Vaccines.

Kreiter S, Diken M, Selmi A, Petschenka J, Türeci Ö, Sahin U.

Methods Mol Biol. 2016;1428:163-75. doi: 10.1007/978-1-4939-3625-0_11.

PMID:
27236799
24.

Characterization of the first-in-class T-cell-engaging bispecific single-chain antibody for targeted immunotherapy of solid tumors expressing the oncofetal protein claudin 6.

Stadler CR, Bähr-Mahmud H, Plum LM, Schmoldt K, Kölsch AC, Türeci Ö, Sahin U.

Oncoimmunology. 2015 Oct 29;5(3):e1091555. eCollection 2016 Mar.

25.

Targeting the Heterogeneity of Cancer with Individualized Neoepitope Vaccines.

Türeci Ö, Vormehr M, Diken M, Kreiter S, Huber C, Sahin U.

Clin Cancer Res. 2016 Apr 15;22(8):1885-96. doi: 10.1158/1078-0432.CCR-15-1509. Review.

26.

The Human Vaccines Project: A roadmap for cancer vaccine development.

Romero P, Banchereau J, Bhardwaj N, Cockett M, Disis ML, Dranoff G, Gilboa E, Hammond SA, Hershberg R, Korman AJ, Kvistborg P, Melief C, Mellman I, Palucka AK, Redchenko I, Robins H, Sallusto F, Schenkelberg T, Schoenberger S, Sosman J, Türeci Ö, Van den Eynde B, Koff W, Coukos G.

Sci Transl Med. 2016 Apr 13;8(334):334ps9. doi: 10.1126/scitranslmed.aaf0685. Review.

PMID:
27075624
27.

Luciferase mRNA Transfection of Antigen Presenting Cells Permits Sensitive Nonradioactive Measurement of Cellular and Humoral Cytotoxicity.

Omokoko TA, Luxemburger U, Bardissi S, Simon P, Utsch M, Breitkreuz A, Türeci Ö, Sahin U.

J Immunol Res. 2016;2016:9540975. doi: 10.1155/2016/9540975. Epub 2016 Jan 5.

28.

Mutanome Engineered RNA Immunotherapy: Towards Patient-Centered Tumor Vaccination.

Vormehr M, Schrörs B, Boegel S, Löwer M, Türeci Ö, Sahin U.

J Immunol Res. 2015;2015:595363. doi: 10.1155/2015/595363. Epub 2015 Dec 30. Review.

29.

Mutanome directed cancer immunotherapy.

Vormehr M, Diken M, Boegel S, Kreiter S, Türeci Ö, Sahin U.

Curr Opin Immunol. 2016 Apr;39:14-22. doi: 10.1016/j.coi.2015.12.001. Epub 2015 Dec 21. Review.

PMID:
26716729
30.

Chromatin Immunoprecipitation Assay to Identify Genomic Binding Sites of Regulatory Factors.

Wagner M, Jung J, Koslowski M, Türeci Ö, Tiwari VK, Sahin U.

Methods Mol Biol. 2016;1366:53-65. doi: 10.1007/978-1-4939-3127-9_6.

PMID:
26585127
31.

Efficient Reprogramming of Human Fibroblasts and Blood-Derived Endothelial Progenitor Cells Using Nonmodified RNA for Reprogramming and Immune Evasion.

Poleganov MA, Eminli S, Beissert T, Herz S, Moon JI, Goldmann J, Beyer A, Heck R, Burkhart I, Barea Roldan D, Türeci Ö, Yi K, Hamilton B, Sahin U.

Hum Gene Ther. 2015 Nov;26(11):751-66. doi: 10.1089/hum.2015.045. Epub 2015 Oct 1.

PMID:
26381596
32.

Humoral immune responses of lung cancer patients against the Transmembrane Phosphatase with TEnsin homology (TPTE).

Kuemmel A, Simon P, Breitkreuz A, Röhlig J, Luxemburger U, Elsäßer A, Schmidt LH, Sebastian M, Sahin U, Türeci Ö, Buhl R.

Lung Cancer. 2015 Nov;90(2):334-41. doi: 10.1016/j.lungcan.2015.07.012. Epub 2015 Jul 30.

PMID:
26350112
33.

CXorf61 is a target for T cell based immunotherapy of triple-negative breast cancer.

Paret C, Simon P, Vormbrock K, Bender C, Kölsch A, Breitkreuz A, Yildiz Ö, Omokoko T, Hubich-Rau S, Hartmann C, Häcker S, Wagner M, Roldan DB, Selmi A, Türeci Ö, Sahin U.

Oncotarget. 2015 Sep 22;6(28):25356-67. doi: 10.18632/oncotarget.4516.

34.

Retrieval of functional TCRs from single antigen-specific T cells: Toward individualized TCR-engineered therapies.

Omokoko T, Simon P, Türeci Ö, Sahin U.

Oncoimmunology. 2015 Mar 19;4(7):e1005523. eCollection 2015 Jul.

35.

Erratum: Mutant MHC class II epitopes drive therapeutic immune responses to cancer.

Kreiter S, Vormehr M, van de Roemer N, Diken M, Löwer M, Diekmann J, Boegel S, Schrörs B, Vascotto F, Castle JC, Tadmor AD, Schoenberger SP, Huber C, Türeci Ö, Sahin U.

Nature. 2015 Jul 16;523(7560):370. doi: 10.1038/nature14567. Epub 2015 Jun 3. No abstract available.

PMID:
26040715
36.

Mutant MHC class II epitopes drive therapeutic immune responses to cancer.

Kreiter S, Vormehr M, van de Roemer N, Diken M, Löwer M, Diekmann J, Boegel S, Schrörs B, Vascotto F, Castle JC, Tadmor AD, Schoenberger SP, Huber C, Türeci Ö, Sahin U.

Nature. 2015 Apr 30;520(7549):692-6. doi: 10.1038/nature14426. Epub 2015 Apr 22. Erratum in: Nature. 2015 Jul 16;523(7560):370.

37.

Translation of genomics-guided RNA-based personalised cancer vaccines: towards the bedside.

Boisguérin V, Castle JC, Loewer M, Diekmann J, Mueller F, Britten CM, Kreiter S, Türeci Ö, Sahin U.

Br J Cancer. 2014 Oct 14;111(8):1469-75. doi: 10.1038/bjc.2013.820. Review.

38.

Functional TCR retrieval from single antigen-specific human T cells reveals multiple novel epitopes.

Simon P, Omokoko TA, Breitkreuz A, Hebich L, Kreiter S, Attig S, Konur A, Britten CM, Paret C, Dhaene K, Türeci Ö, Sahin U.

Cancer Immunol Res. 2014 Dec;2(12):1230-44. doi: 10.1158/2326-6066.CIR-14-0108. Epub 2014 Sep 22.

39.

mRNA-based therapeutics--developing a new class of drugs.

Sahin U, Karikó K, Türeci Ö.

Nat Rev Drug Discov. 2014 Oct;13(10):759-80. doi: 10.1038/nrd4278. Epub 2014 Sep 19. Review.

PMID:
25233993
40.

Phenotyping of peripheral blood mononuclear cells of patients with advanced heavily pre-treated adenocarcinoma of the stomach and gastro-esophageal junction.

Kuehnle MC, Attig S, Britten CM, Schulze-Bergkamen H, Lordick F, von Wichert G, Thuss-Patience P, Stein A, Schuler M, Bassermann F, Sahin U, Türeci O.

Cancer Immunol Immunother. 2014 Dec;63(12):1273-84. doi: 10.1007/s00262-014-1596-x. Epub 2014 Aug 28.

PMID:
25164876
41.

mTOR inhibition improves antitumor effects of vaccination with antigen-encoding RNA.

Diken M, Kreiter S, Vascotto F, Selmi A, Attig S, Diekmann J, Huber C, Türeci Ö, Sahin U.

Cancer Immunol Res. 2013 Dec;1(6):386-92. doi: 10.1158/2326-6066.CIR-13-0046. Epub 2013 Sep 20.

42.

Mutated tumor alleles are expressed according to their DNA frequency.

Castle JC, Loewer M, Boegel S, Tadmor AD, Boisguerin V, de Graaf J, Paret C, Diken M, Kreiter S, Türeci Ö, Sahin U.

Sci Rep. 2014 Apr 22;4:4743. doi: 10.1038/srep04743.

43.

Aberrantly activated claudin 6 and 18.2 as potential therapy targets in non-small-cell lung cancer.

Micke P, Mattsson JS, Edlund K, Lohr M, Jirström K, Berglund A, Botling J, Rahnenfuehrer J, Marincevic M, Pontén F, Ekman S, Hengstler J, Wöll S, Sahin U, Türeci O.

Int J Cancer. 2014 Nov 1;135(9):2206-14. doi: 10.1002/ijc.28857. Epub 2014 Apr 8.

44.

T-cell receptor transfer into human T cells with ecotropic retroviral vectors.

Koste L, Beissert T, Hoff H, Pretsch L, Türeci Ö, Sahin U.

Gene Ther. 2014 May;21(5):533-8. doi: 10.1038/gt.2014.25. Epub 2014 Apr 3.

PMID:
24694535
45.

Immunomic, genomic and transcriptomic characterization of CT26 colorectal carcinoma.

Castle JC, Loewer M, Boegel S, de Graaf J, Bender C, Tadmor AD, Boisguerin V, Bukur T, Sorn P, Paret C, Diken M, Kreiter S, Türeci Ö, Sahin U.

BMC Genomics. 2014 Mar 13;15:190. doi: 10.1186/1471-2164-15-190.

46.

Peptide microarrays enable rapid mimotope optimization for pharmacokinetic analysis of the novel therapeutic antibody IMAB362.

Schnatbaum K, Schmoldt HU, Daneschdar M, Plum LM, Jansong J, Zerweck J, Kühne Y, Masch A, Wenschuh H, Fiedler M, Türeci Ö, Sahin U, Reimer U.

Biotechnol J. 2014 Apr;9(4):545-54. doi: 10.1002/biot.201300456. Epub 2014 Mar 7.

PMID:
24497417
47.

NCOA3 is a selective co-activator of estrogen receptor α-mediated transactivation of PLAC1 in MCF-7 breast cancer cells.

Wagner M, Koslowski M, Paret C, Schmidt M, Türeci O, Sahin U.

BMC Cancer. 2013 Dec 4;13:570. doi: 10.1186/1471-2407-13-570.

48.

Antigen identification using SEREX.

Sahin U, Türeci O.

Methods Mol Biol. 2013;1061:59-77. doi: 10.1007/978-1-62703-589-7_3.

PMID:
23963930
49.

Claudin 18.2 is a target for IMAB362 antibody in pancreatic neoplasms.

Wöll S, Schlitter AM, Dhaene K, Roller M, Esposito I, Sahin U, Türeci Ö.

Int J Cancer. 2014 Feb 1;134(3):731-9. doi: 10.1002/ijc.28400. Epub 2013 Sep 16.

50.

Tumor fibroblast-derived epiregulin promotes growth of colitis-associated neoplasms through ERK.

Neufert C, Becker C, Türeci Ö, Waldner MJ, Backert I, Floh K, Atreya I, Leppkes M, Jefremow A, Vieth M, Schneider-Stock R, Klinger P, Greten FR, Threadgill DW, Sahin U, Neurath MF.

J Clin Invest. 2013 Apr;123(4):1428-43. doi: 10.1172/JCI63748. Epub 2013 Mar 15.

Supplemental Content

Loading ...
Support Center